Market Overview

Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate

Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate
Related CLVS
22 Stocks Moving In Wednesday's Pre-Market Session
65 Biggest Movers From Yesterday

Clovis Oncology Inc (NASDAQ: CLVS) has emerged as a strong takeover candidate following GlaxoSmithKline plc (NYSE: GSK)'s proposed acquisition of TESARO Inc (NASDAQ: TSRO), according to Gabelli Research.

The Analyst

Analyst Jing He named Clovis as his top pick in 2019. The analyst reiterated a Buy rating on Clovis shares.

The Thesis

The Tesaro deal and Merck & Co., Inc. (NYSE: MRK)'s $5-billion purchase of half of the commercial rights of AstraZeneca plc (NYSE: AZN)'s Lynparza in 2017 leave Clovis as the sole standalone PARP oncology company, giving it a scarcity value, analyst He said in a Tuesday note. (See his track record here.)

Clovis is the most likely takeout target in 2019, with Bristol-Myers Squibb Co (NYSE: BMY), Novartis AG (NYSE: NVS)' Sanofi and Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) among the potential suitors, the analyst said. 

Clovis' Rubraca — a PARP inhibitor — is being evaluated in combination with Bristol-Myers' Opdivo as a first-line maintenance therapy for ovarian cancer in the ATHENA trial, He said. Data from the trial is expected in early 2021.

Although Clovis is behind the AstraZeneca-Merck combine and Tesaro-GSK in development, Clovis is in a better long-term position due to data generated by the Rubraca-Opdivo combination, He said. 

Clovis is evaluating Rubraca as monotherapy to treat prostate cancer in TRITON2 and TRITON3 trials, thr 

The company looks forward to filing application to the FDA by year-end 2019, the analyst said. 

Gabelli views data updates from TRITON2/3 trials at the ASCO meeting in June as the next catalysts for Clovis shares. 

The Price Action

Clovis shares were higher by more than 1 percent at $21.96 at the time of publication Tuesday.

Related Links:

The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings

The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings

Latest Ratings for CLVS

Oct 2018BarclaysMaintainsOverweightOverweight
Oct 2018JP MorganDowngradesOverweightNeutral
Sep 2018Leerink SwannInitiates Coverage OnMarket Perform

View More Analyst Ratings for CLVS
View the Latest Analyst Ratings

Posted-In: Gabelli Jing He oncologyAnalyst Color Biotech Reiteration Analyst Ratings General Best of Benzinga


Related Articles (AZN + BMY)

View Comments and Join the Discussion!

Latest Ratings

CNPRBC CapitalUpgrades34.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

What China's iPhone Ruling Means For Qualcomm And Apple

Roku Under Selling Pressure Amid Report TCL Is Shifting Its Business